Physician profile

Keith R Jackson

Otolaryngology · Roswell, GA

NPI 1225016454

$1,016.64

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$23.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $329.12 2019-2023 Oasys
Spinal Elements, INC. $137.50 2022
Abbott Laboratories $135.49 2022
Intersect Ent, INC. $131.25 2019-2020
Angiodynamics, INC. $100.70 2019
Depuy Synthes Sales INC. $49.13 2021
Bioventus LLC $33.16 2021
Optinose US, INC. $29.72 2019
Aerin Medical INC. $20.60 2020
Dermira, INC. $18.47 2019
Merck Sharp & Dohme LLC $16.84 2019
Straumann USA LLC $14.66 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Keith R Jackson

$1,016.64

in general payments reported 2019-2025

Years
2019-2023
Top company
Stryker Corporation

https://glasscript.com/doctor/10500/keith-r-jackson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.